Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
SpringWorks Therapeutics (SWTX) had Return on Tangible Equity of -19.93% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$49.09M |
|
$-83.19M |
|
$3.53M |
|
$45.56M |
|
$129.62M |
|
$-80.54M |
|
$-2.65M |
|
$-83.19M |
|
$-83.19M |
|
$-83.19M |
|
$-83.19M |
|
$-83.19M |
|
$-83.19M |
|
$-80.54M |
|
$-79.44M |
|
74.89M |
|
74.89M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$356.32M |
|
$19.25M |
|
$149.04M |
|
$505.36M |
|
$82.27M |
|
-- |
|
$5.69M |
|
$87.96M |
|
$417.39M |
|
$417.39M |
|
$417.39M |
|
74.99M |
|
| Cash Flow Statement Financials | |
$-68.76M |
|
$73.39M |
|
$-10.61M |
|
$70.38M |
|
$64.40M |
|
$-5.97M |
|
$29.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.33 |
|
-- |
|
-- |
|
-- |
|
-- |
|
92.81% |
|
-164.07% |
|
-164.07% |
|
-- |
|
-169.47% |
|
-169.47% |
|
$-68.79M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.28 |
|
1.22 |
|
73.98 |
|
-19.93% |
|
|
Return on Tangible Equity |
-19.93% |
-16.46% |
|
-19.93% |
|
$5.57 |
|
$-0.92 |
|
$-0.92 |
|